Watch for Nemolizumab for Moderate to Severe Eczema

July 2026

Nemolizumab (Nemluvio) will add to the growing list of biologic options for eczema.

It’s an injectable “monoclonal antibody”...similar to dupilumab (Dupixent), lebrikizumab (Ebglyss), and tralokinumab (Adtralza)...for moderate to severe eczema.

They help eczema symptoms (itching, etc) by limiting inflammation.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Lyme Disease Brush Up on Tick Bites and Preventing Lyme Disease
Rumor vs Truth Listen for Common Claims About Laxatives and Constipation
Insulin Watch for Errors With Newer Insulins
Insomnia Understand the Role of the First Rx Melatonin for Insomnia
Diabetes Prevent Errors With the New Optimized Rybelsus
Stroke Look for Antiplatelet Meds to Help Prevent Another Stroke
Myocardial Infarction Be Ready to Help Optimize Meds After a Heart Attack
Eczema Watch for Nemolizumab for Moderate to Severe Eczema

Watch for Nemolizumab for Moderate to Severe Eczema

Practical advice for a better career, with unlimited access to CE

Table of Contents